Tissue factor pathway inhibitor
FunctionTissue factor pathway inhibitor (TFPI) is a protease inhibitor which inhibits coagulation factor Xa and VIIa[1]. TFPI contains three Kunitz domains. The Kunitz domain is disulfide-rich and is arranged to form a twisted two-stranded antiparallel β sheet followed by an α helix. Kunitz I domain inhibits VIIa coagulation factor while Kunitz II domain inhibits Xa. DiseaseRelevanceThe expression of hTFPI-2 in tumors is inversely related to their malignancy[2]. TFPI inhibitors are investigated as therapeutic agents agains hemophilia[3]. Structural highlights |
| ||||||||||
3D Structures of tissue factor pathway inhibitor3D Structures of tissue factor pathway inhibitor
Updated on 14-September-2016
1adz – hTFPI-1 kunitz domain II (mutant) – human - NMR
1irh – hTFPI-1 kunitz domain III - NMR
1tfx – hTFPI-1 kunitz domain II + trypsin
1zr0 – hTFPI-2 kunitz domain I + trypsin
4dtg – hTFPI-1 kunitz domain II + antibody
4bqd – hTFPI-1 kunitz domain I + peptide
ReferencesReferences
- ↑ Kato H. Tissue factor pathway inhibitor; its structure, function and clinical significance. Pol J Pharmacol. 1996 Jan-Feb;48(1):67-72. PMID:9112630
- ↑ Sierko E, Wojtukiewicz MZ, Kisiel W. The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost. 2007 Oct;33(7):653-9. PMID:18000791 doi:http://dx.doi.org/10.1055/s-2007-991532
- ↑ Peterson JA, Maroney SA, Mast AE. Targeting TFPI for hemophilia treatment. Thromb Res. 2016 May;141 Suppl 2:S28-30. doi: 10.1016/S0049-3848(16)30359-0. PMID:27207418 doi:http://dx.doi.org/10.1016/S0049-3848(16)30359-0